Expression of multidrug resistance-related transporters in human breast carcinoma.
about
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significanceRole of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interferenceFolate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasisThe challenge of exploiting ABCG2 in the clinic.ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma.The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).Role of the breast cancer resistance protein (ABCG2) in drug transport.DualChip microarray as a new tool in cancer research.Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patientsABCG2: determining its relevance in clinical drug resistance.Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cellsExpression of the breast cancer resistance protein and 5-fluorouracil resistance in clinical breast cancer tissue specimens.ABCG2: the key to chemoresistance in cancer stem cells?Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.Human ABCG2: structure, function, and its role in multidrug resistance.Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer.Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours.Drug transporters in breast cancer: response to anthracyclines and taxanes.Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis.Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.Multidrug resistance in breast cancer: from in vitro models to clinical studies.Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma.Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.New chemosensitivity test using a thermo-reversible gelation polymer for recurrent gynecologic cancer patients and a preliminary study of mechanisms of anticancer drug resistance.Increased expression of lung resistance-related protein in lower grade urothelial carcinoma of the renal pelvis and ureter.
P2860
Q24813854-AD7CD0BD-07D0-45E9-B116-07A89AA5AAD0Q27863394-7FEAFF66-DC22-4653-B004-196712ACE7AEQ28541362-2860F4A2-92B7-4C18-A68D-10A6172CD779Q33200355-1EBF640F-6935-46A0-AB36-F1A5C60D84CFQ34204238-8486E0FA-3ADD-40FC-9077-379C315A2D4DQ34656357-F14274CB-8D50-4789-B361-90159C1108EDQ34968909-E7D9AD9C-2348-47C6-90E2-439CDAE4153EQ35318963-37C2939E-6A8E-4E69-A263-F69AC74DDC8DQ36052743-6069EAA8-90AE-47C6-BF4A-FC506A066CBEQ36250753-420727DE-4983-4A0D-8FB1-CBD5B5E3EF6DQ36481097-C206E14F-6F0F-4635-AD16-899FF074D003Q36613823-381B24A3-1A63-4055-8D32-1E7F489F95B6Q36745478-4F867FC1-57C3-49CB-9895-EC66DF9E56FEQ37511825-C5884CB1-92C9-4CF0-B77B-3BEC1CEE9BFFQ37560927-4878071B-C341-49EC-B9FF-6EB1CA043274Q37587219-D31079D4-7BB4-4995-AD8E-5AE2AAB74C80Q37735253-A44CBCC2-4AE9-44FB-A8D0-B9F927A09203Q38003156-38A58FD6-7F14-4B15-B2AE-21D1415582E9Q38287959-C2D1E859-D61B-4E62-9C84-711A063F0403Q38308507-CF2493C7-9878-4823-8A3C-085DEC43EE2DQ38575008-DFAE1DF1-89A6-4566-8D5F-F6541C2F8031Q39668730-2B28A3D3-0094-44D2-827D-BF150A0AD5B9Q40156747-EE3866AA-D34B-4A2B-9BA9-992A06B1C9CAQ40574551-5698985A-AE35-4C29-AE82-C79D23C79605Q40633176-E3E61EE8-ED41-4EED-88AE-9C130DB2F6A1Q42695791-CDA2A9CB-436E-4608-A1C9-A705F595112AQ43861419-0619C4CC-CB38-401D-BC18-C79905A2E3DEQ44128397-A20C4A2C-44F3-4A48-AECA-7433D7C7D69CQ46988985-FE85C3A0-139B-45B9-A0E7-EC5786B0B5ECQ49679382-C46B554B-5AEA-457E-AB84-9A22D059822AQ51124010-CD3768F6-3549-40CA-9840-214C9A4EECA0Q54700830-4A3BFDF5-8282-415D-A868-89B56EDC985C
P2860
Expression of multidrug resistance-related transporters in human breast carcinoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Expression of multidrug resistance-related transporters in human breast carcinoma.
@en
Expression of multidrug resistance-related transporters in human breast carcinoma.
@nl
type
label
Expression of multidrug resistance-related transporters in human breast carcinoma.
@en
Expression of multidrug resistance-related transporters in human breast carcinoma.
@nl
prefLabel
Expression of multidrug resistance-related transporters in human breast carcinoma.
@en
Expression of multidrug resistance-related transporters in human breast carcinoma.
@nl
P2093
P2860
P1476
Expression of multidrug resistance-related transporters in human breast carcinoma.
@en
P2093
K Nakayama
M Fukumoto
Y Takebayashi
P2860
P304
P356
10.1111/J.1349-7006.2001.TB01115.X
P577
2001-04-01T00:00:00Z